Glucose - Regulating Drugs Aid COVID - 19 Outcomes in Patients With Diabetes
Findings include GLP - 1R agonists and pioglitazone use, with drop in hospital admissions (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 9, 2021 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Infections, Internal Medicine, Critical Care, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Newer Antidiabetic Drugs Linked to Improved Liver Enzymes, Steatosis Newer Antidiabetic Drugs Linked to Improved Liver Enzymes, Steatosis
Early evidence suggests that newer diabetes drugs such as pioglitazone may improve liver enzymes and hepatic steatosis and could possibly be useful in treating non-alcoholic fatty liver disease (NAFLD), researchers say.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 6, 2020 Category: Endocrinology Tags: Gastroenterology News Source Type: news

FDA testing metformin for traces of nitrosamines
MHRA aware of issue and advises patients to continue to taking their diabetes medicine Related items fromOnMedica People on statins at greater risk of skin infections and diabetes Raised risk of MI and mortality when starting sulfonylurea Use of DPP-4 inhibitors associated with increased risk of IBD Vitamin D does not reduce kidney damage in type 2 diabetes Use pioglitazone only in selected patients, says EMA guidance (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 9, 2019 Category: UK Health Source Type: news

Diabetes drug can relieve smoking withdrawal symptoms, study says
An Italian experiment on rats and mice found pioglitazone - sold under the brand name Actos - weakened the effects of nicotine withdrawal. (Source: the Mail online | Health)
Source: the Mail online | Health - November 4, 2019 Category: Consumer Health News Source Type: news

Macleods Pharma USA Inc recalls 31,968 bottles of diabetes drug in US
Macleods Pharma USA Inc has declared Pioglitazone Hydrochloride tablets used for treatment of diabetes in America to be superpotent which was manufactured in Baddi, Himachal Pradesh. The product was shipped to 8 distributors in US, USFDA reported. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 27, 2019 Category: Pharmaceuticals Source Type: news

Polycystic Ovary Syndrome Awareness Month
September is   Polycystic Ovary Syndrome Awareness Month and is an excellent time to focus on the latest Cochrane evidence.Polycystic ovary syndrome (PCOS) is a very common condition affecting 8% to 13% of women. Being overweight worsens all clinical features of PCOS. These clinical features include reproductive issues such as reduced frequency of ovulation and irregular menstrual cycles, reduced fertility, polycystic ovaries onultrasound and high levels of male hormones such as testosterone, which can cause unwanted facial or body hair growth and acne. PCOS is also associated with metabolic features, withrisk factors for...
Source: Cochrane News and Events - September 3, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure
[09-17-2010] The U.S. Food and Drug Administration (FDA) is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone), is associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines
[8-4-2011] The U.S. Food and Drug Administration (FDA) is informing the public that the Agency has approved updated drug labels for the pioglitazone-containing medicines to include safety information that the use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Diabetes Drug, Pioglitazone, May Prevent Secondary Strokes (CME/CE)
(MedPage Today) -- Post hoc IRIS analysis points to benefit, although adverse effects still widely seen as off-putting (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 16, 2019 Category: Primary Care Source Type: news

Stroke Patients With Prediabetes Benefit From Pioglitazone
(MedPage Today) -- IRIS analysis finds lower CV, diabetes risk in this subgroup (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - February 8, 2019 Category: Neurology Source Type: news

High glucose spikes are common in 'healthy' people
Continuous glucose monitoring shows levels vary throughout day in people considered normoglycaemic Related items fromOnMedica Weight Watchers helped stave off type 2 diabetes GPs failing to follow women at risk after gestational diabetes Experts query risks of pioglitazone Diabetes training scheme launched for GPs HbA1c improves just as much on dieting only two days a week (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 25, 2018 Category: UK Health Source Type: news